Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test

Yvo Ghoos, Bart Maes, Benny Geypens, +4

Gastroenterology

PhysiologyGastroenterologyPulmonary PhysiologyLung MechanicsGas Exchange Process +3

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

Hallvard Holdaas, Bengt Fellström, Alan G. Jardine, +13

The Lancet

TransplantationCardiovascular DiseaseKidney TransplantKidney TransplantationCardiac Outcomes +7

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Bengt Fellström, Jonathan Barratt, H. Terence Cook, +14

The Lancet

Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study

Hallvard Holdaas, Bengt Fellström, Edward Cole, +11

American Journal of Transplantation

TransplantationCardiovascular DiseaseKidney TransplantKidney TransplantationTransplantation Medicine +6

Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study

Pieter Evenepoel, Karolien Claes, Dirk Kuypers, +3

Nephrology Dialysis Transplantation

Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study

Bart Maes, Raymond Oyen, Kathleen Claes, +5

Kidney International

GlomerulonephritisMycophenolate MofetilRenal FunctionKidney FailureChronic Kidney Disease +6

Influence of dietary protein supplements on the formation of bacterial metabolites in the colon.

Benny Geypens, D. Claus, Pieter Evenepoel, +5

Gut

Prospective Study on Late Consequences of Subclinical Non-Compliance with Immunosuppressive Therapy in Renal Transplant Patients

H. Vlaminck, Bart Maes, Georges Evers, +4

American Journal of Transplantation

Transplant RejectionRenal Transplant PatientsUrologyTransplantationKidney Transplant +9

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, +704

The Lancet

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen, +153

Kidney International